Iovance Biotherapeutics (IOVA) Change in Accured Expenses (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Change in Accured Expenses of -$21.0 million for Q1 2026, down 1035.02% year-over-year from $2.2 million in Q1 2025, and down 199.38% quarter-over-quarter from $21.2 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Change in Accured Expenses for 15 consecutive years, with -$21.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 1035.02% year-over-year to -$21.0 million; the TTM figure through Mar 2026 stood at $5.3 million (down 84.19% YoY), while the FY2025 annual figure was $28.6 million, up 233.84% from the prior year.
- Change in Accured Expenses fell to -$21.0 million in Q1 2026 per IOVA's latest filing, from $21.2 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $21.2 million in Q4 2025 and bottomed at -$23.0 million in Q1 2024.
- Historically, Change in Accured Expenses has averaged $1.8 million across 5 years, with a median of $3.5 million in 2023.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 934.65% — and 2026, when it sank 1035.02%.
- Iovance Biotherapeutics' Change in Accured Expenses stood at $909000.0 in 2022, then surged by 934.65% to $9.4 million in 2023, then tumbled by 56.58% to $4.1 million in 2024, then soared by 418.34% to $21.2 million in 2025, then plunged by 199.38% to -$21.0 million in 2026.
- Business Quant data shows IOVA's Change in Accured Expenses at -$21.0 million in Q1 2026, $21.2 million in Q4 2025, and $5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | -8.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.62 Mn |
| Jun 30, 2026 | -8.62 Mn |
| Mar 31, 2026 | -21.04 Mn |
| Mar 31, 2026 | -21.04 Mn |
| Dec 31, 2025 | 21.17 Mn |
| Dec 31, 2025 | 21.17 Mn |
| Sep 30, 2025 | 5.50 Mn |
| Sep 30, 2025 | 5.50 Mn |
| Jun 30, 2025 | -281,000.00 |
| Jun 30, 2025 | -281,000.00 |
| Mar 31, 2025 | 2.25 Mn |
| Mar 31, 2025 | 2.25 Mn |
| Dec 31, 2024 | 4.08 Mn |
| Dec 31, 2024 | 4.08 Mn |
| Sep 30, 2024 | 12.70 Mn |
| Sep 30, 2024 | 12.70 Mn |
| Jun 30, 2024 | 14.81 Mn |
| Jun 30, 2024 | 14.81 Mn |
| Mar 31, 2024 | -23.02 Mn |
| Mar 31, 2024 | -23.02 Mn |